查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2110255

2026-2034年全球誘導多功能細胞（iPS細胞）生產市場規模、佔有率、趨勢和成長分析報告

Global Induced Pluripotent Stem Cells Production Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 227 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球誘導多功能細胞（iPS細胞）生產市場預計將從2025年的22.3億美元成長至2034年的53.1億美元，2026年至2034年的複合年成長率（CAGR）為10.11%。全球iPS細胞生產市場呈現強勁成長勢頭，主要得益於人們對再生醫學和細胞療法的日益關注。 iPS細胞是多功能細胞重編程為胚胎樣的狀態，並可分化成多種細胞類型。這項技術在疾病建模、藥物篩檢和組織再生方面具有巨大潛力。幹細胞生物學研究的活性化以及慢性疾病盛行率的上升正在推動市場成長。

推動該市場發展的主要因素是iPS細胞在個人化醫療和先進療法開發中的應用日益廣泛。製藥公司利用iPS細胞測試藥物的毒性和療效，降低後期臨床試驗失敗的風險。政府的支持性法規、資助計畫以及研究機構與生技公司之間的合作也加速了產能的提升。重編程技術的進步使這一過程更加高效且經濟。

預計未來市場將快速成長，這主要得益於幹細胞療法臨床試驗的增加。自動化生產系統和標準化流程的開發將進一步提升市場的擴充性。亞太地區憑藉其不斷完善的生物技術基礎設施，正崛起為領先區域。隨著再生醫學的日益普及，iPS細胞生產市場有望實現長期持續成長和創新。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：本節詳細評估影響市場成長的主要促進因素、阻礙因素、機會和挑戰。內容涵蓋技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球誘導多功能細胞（iPS細胞）生產市場：依製程分類

  • 市場分析、洞察與預測
  • 手動生成iPS細胞的過程
  • 自動化iPS細胞製造程序

第5章 全球誘導性多功能細胞（iPS細胞）生產市場：依工作流程分類

  • 市場分析、洞察與預測
  • 再程式化
  • 細胞培養
  • 細胞表徵/分析
  • 工程
  • 其他

第6章 全球誘導性多功能細胞（iPS細胞）生產市場：依產品分類

  • 市場分析、洞察與預測
  • 設備/器材
  • 自動化平台
  • 耗材和工具包
  • 服務

第7章 全球誘導性多功能細胞（iPS細胞）生產市場：依應用領域分類

  • 市場分析、洞察與預測
  • 藥物發現及新藥研發
  • 再生醫學
  • 毒性測試
  • 其他

第8章 誘導多功能細胞（iPS細胞）的全球市場：依最終用途分類

  • 市場分析、洞察與預測
  • 研究和學術機構
  • 生物技術和製藥公司
  • 醫院和診所

第9章 全球誘導多功能細胞（iPS細胞）生產市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Lonza
    • Axol Bioscience Ltd
    • Evotec
    • Hitachi Ltd
    • Reprocell Inc
    • Merck KGaA
    • Reprocells Inc
    • Fate Therapeutics
    • Thermo Fisher Scientific Inc
    • StemCellsFactory III
    • Applied StemCells Inc
簡介目錄
Product Code: VMR112110349

The global induced pluripotent stem cells production market size is expected to reach USD 5.31 Billion in 2034 from USD 2.23 Billion in 2025, growing at a CAGR of 10.11 during 2026-2034.The Global Induced Pluripotent Stem Cells (iPSCs) Production Market is witnessing strong growth due to rising interest in regenerative medicine and cell-based therapies. iPSCs are adult cells that are reprogrammed to an embryonic-like state, allowing them to differentiate into various cell types. This technology offers significant potential in disease modeling, drug screening, and tissue regeneration. Increasing research activities in stem cell biology and the growing prevalence of chronic diseases are driving the market forward.

A major driver for this market is the expanding application of iPSCs in personalized medicine and advanced therapeutic development. Pharmaceutical companies are using iPSCs to test drug toxicity and efficacy, reducing the risk of failure in later clinical stages. Supportive government regulations, funding programs, and partnerships between research institutes and biotech firms are also accelerating production capabilities. Technological improvements in reprogramming methods have made the process more efficient and cost-effective.

Looking ahead, the market is expected to grow rapidly with increasing clinical trials involving stem cell therapies. The development of automated production systems and standardized protocols will further enhance scalability. Asia-Pacific is emerging as a strong region due to expanding biotechnology infrastructure. As regenerative medicine becomes more mainstream, the iPSCs production market is likely to see sustained long-term growth and innovation.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Process

  • Manual iPSC Production Process
  • Automated iPSC Production Process

By Workflow

  • Reprogramming
  • Cell Culture
  • Cell Characterization/Analysis
  • Engineering
  • Others

By Product

  • Instruments/Devices
  • Automated Platforms
  • Consumables & Kits
  • Services

By Application

  • Drug Development & Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Others

By End Use

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

COMPANIES PROFILED

  • Lonza, Axol Bioscience Ltd., Evotec, Hitachi Ltd., Reprocell Inc., Merck KGaA, Reprocells Inc., Fate Therapeutics, Thermo Fisher Scientific Inc., StemCellsFactory III, Applied StemCells Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY PROCESS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Process
  • 4.2. Manual iPSC Production Process Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Automated iPSC Production Process Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY WORKFLOW 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Workflow
  • 5.2. Reprogramming Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Cell Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Cell Characterization/Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Product
  • 6.2. Instruments/Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Automated Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Consumables & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Application
  • 7.2. Drug Development & Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Regenerative Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Toxicology Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY END USE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End Use
  • 8.2. Research & Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Biotechnology & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Process
    • 9.2.2 By Workflow
    • 9.2.3 By Product
    • 9.2.4 By Application
    • 9.2.5 By End Use
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Process
    • 9.3.2 By Workflow
    • 9.3.3 By Product
    • 9.3.4 By Application
    • 9.3.5 By End Use
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Process
    • 9.4.2 By Workflow
    • 9.4.3 By Product
    • 9.4.4 By Application
    • 9.4.5 By End Use
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Process
    • 9.5.2 By Workflow
    • 9.5.3 By Product
    • 9.5.4 By Application
    • 9.5.5 By End Use
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Process
    • 9.6.2 By Workflow
    • 9.6.3 By Product
    • 9.6.4 By Application
    • 9.6.5 By End Use
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Lonza
    • 11.2.2 Axol Bioscience Ltd
    • 11.2.3 Evotec
    • 11.2.4 Hitachi Ltd
    • 11.2.5 Reprocell Inc
    • 11.2.6 Merck KGaA
    • 11.2.7 Reprocells Inc
    • 11.2.8 Fate Therapeutics
    • 11.2.9 Thermo Fisher Scientific Inc
    • 11.2.10 StemCellsFactory III
    • 11.2.11 Applied StemCells Inc